CAMP4 Therapeutics
CAMP
39 hedge funds and large institutions have $50.7M invested in CAMP4 Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
8% more funds holding
Funds holding: 36 → 39 (+3)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
0.88% less ownership
Funds ownership: 63.76% → 62.88% (-0.88%)
24% less capital invested
Capital invested by funds: $67.1M → $50.7M (-$16.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$222K |
| 2 |
BlackRock
New York
|
+$149K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$94K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$70.2K |
| 5 |
Bank of New York Mellon
New York
|
+$63.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.04M |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$213K |
| 3 |
Norges Bank
Oslo,
Norway
|
-$183K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$63.8K |
| 5 |
JP Morgan Chase
New York
|
-$63K |
CAMP Hedge Fund Activity: Q1 2025 in Review
39 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in CAMP4 Therapeutics (CAMP) for Q1 2025, worth a combined $50.7M — down 24% from $67.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CAMP positions and 4 closed out — a net gain of 3 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $222K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.04M sold.
- 39 institutional investors held CAMP4 Therapeutics (CAMP) as of Q1 2025, up from 36 in Q4 2024.
- Funds reported $50.7M of CAMP4 Therapeutics stock for Q1 2025, down 24% quarter-over-quarter.
- 7 funds opened new CAMP4 Therapeutics positions in Q1 2025 and 4 closed out, a net change of +3 holders.
- The largest CAMP4 Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $222K added.
- The largest CAMP4 Therapeutics seller in Q1 2025 was Citadel Advisors, an estimated $1.04M sold.
Based on aggregated 13F filings for Q1 2025.